{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:42:26Z","timestamp":1793029346582,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.nucmedbio.2026.109678","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:59:17Z","timestamp":1788188357000},"page":"109678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Small-scale theranostic radiopharmaceutical production using cold kits: a green chemistry perspective"],"prefix":"10.1016","volume":"160-161","author":[{"given":"Sandile","family":"Sibiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayed","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietske M.","family":"Rubow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Vlk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"du Plessis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Rijn","family":"Zeevaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike M.","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ebenhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janke","family":"Kleynhans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109678_bb0005","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41893-022-01050-z","article-title":"Green chemistry as just chemistry","volume":"6","author":"Lane","year":"2023","journal-title":"Nat Sustain"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109678_bb0010","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1021\/acs.chemrev.1c00631","article-title":"Green chemistry in the synthesis of pharmaceuticals","volume":"122","author":"Kar","year":"2022","journal-title":"Chem Rev"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109010","article-title":"How green are radiopharmaceutical sciences?","volume":"144-145","author":"Pichler","year":"2025","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1039\/B918763B","article-title":"Green chemistry: principles and practice","volume":"39","author":"Anastas","year":"2010","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1053\/j.semnuclmed.2024.06.001","article-title":"Expanding role for Gallium-68 PET imaging in oncology","volume":"54","author":"Kleynhans","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"16","key":"10.1016\/j.nucmedbio.2026.109678_bb0030","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1039\/D5CS00392J","article-title":"Gallium-68 labelled radiopharmaceuticals: a review","volume":"54","author":"Tanwar","year":"2025","journal-title":"Chem Soc Rev"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109678_bb0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2967\/jnumed.124.269401","article-title":"Reflections on the demand for PSMA- and SSTR-targeted radiopharmaceutical therapies: why we were wrong (and why we will be right eventually)","volume":"66","author":"Czernin","year":"2025","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109678_bb0040","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12032-025-03061-0","article-title":"Theranostics in nuclear medicine: the era of precision oncology","volume":"42","author":"Ghandi","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0045","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1021\/acs.bioconjchem.1c00010","article-title":"Recent breakthrough in 68Ga-radiopharmaceuticals cold kits for convenient PET radiopharmacy","volume":"32","author":"Satpati","year":"2021","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13139-025-00956-8","article-title":"Automated synthesis of radiopharmaceuticals: technology, applications, and regulatory perspectives","volume":"60","author":"Ko","year":"2026","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109678_bb0055","first-page":"159","article-title":"Manual vs automaed 68Ga-radiolabelling \u2013 a comparison of optimized process","volume":"63","author":"Meisenheimer","year":"2019","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0060","article-title":"Cold kit labeling: the future of 68Ga radiopharmaceuticals?","volume":"9","author":"Lepareur","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0065","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8160134","article-title":"Labelling of 90Y and 177Lu-DOTA-bioconjugates for targeted radionuclide therapy: a comparison among manual, semiautomated, and fully automated synthesis","author":"Iori","year":"2017","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1555712","article-title":"Preparation of 177Lu-PSMA-617 in hospital radiopharmacy: convenient formulation of a clinical dose using a single-vial freeze-dried PSMA-617 kit developed in-house","author":"Guleria","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2020.109452","article-title":"A comparison of labelling characteristics of manual and automated synthesis methods for gallium-68 labelled ubiquicidin","volume":"168","author":"Le Roux","year":"2021","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109678_bb0080","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3390\/ph18060906","article-title":"Revolutionizing prostate cancer detection: the role of approved PSMA-PET imaging agents","volume":"18","author":"Hennrich","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.7447","article-title":"Prospective of 68Ga-radiopharmaceutical development","volume":"4","author":"Velikyan","year":"2014","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0090","doi-asserted-by":"crossref","first-page":"49586","DOI":"10.1039\/C7RA09076E","article-title":"Comparison of macrocylic and acyclic chelators for gallium-68 radiolabelling","volume":"7","author":"Tsionou","year":"2017","journal-title":"RSC Adv"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109678_bb0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.semnuclmed.2016.04.003","article-title":"Bifunctional gallium-68 chelators: past, present, and future","volume":"46","author":"Spang","year":"2016","journal-title":"Semin Nucl Med"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5005\/jp-journals-10028-1052","article-title":"68Ge\/68Ga generators and 68Ga radiopharmaceutical chemistry on their way into a new century","volume":"47","author":"R\u00f6sch","year":"2013","journal-title":"J Postgrad Med Educ Res"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109678_bb0105","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/MNM.0000000000000275","article-title":"Development of a simple kit-based method for preparation of pharmaceutical-grade 68Ga-DOTATOC","volume":"36","author":"Asti","year":"2015","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.apradiso.2018.02.002","article-title":"Clinical experience with indigenous kit-based preperation of 68Ga-DOTATOC using commerial 68Ge\/68Ga generator","volume":"136","author":"Pandy","year":"2018","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0115","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s11307-017-1077-7","article-title":"Development and evaluation of user-friendly single vial DOTA-peptide kit formulations, specifically designed for radiolabeling with 68Ga from a tin dioxide 68Ge\/68Ga generator","volume":"19","author":"Prince","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0120","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11307-017-1072-z","article-title":"Preliminary PET\/CT with somatostatin analogs [68Ga]DOTAGA-TATE and [68Ga]DOTAGA-TOC","volume":"19","author":"Sapati","year":"2017","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13550-019-0516-7","article-title":"Instant kit perparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC","volume":"9","author":"Sinnes","year":"2019","journal-title":"EJNMMI Res"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109678_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/molecules200814860","article-title":"Development of a single vial kit solution for radiolabeling of 68Ga-DKFZ-PSMA-11 and its performance in prostate cancer patients","volume":"20","author":"Ebenhan","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0135","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11307-016-0943-z","article-title":"Convenient preperation of [68Ga]DKFZ-PSMA-11 using a robust single-vial kit and demonstration of its clinical efficacy","volume":"18","author":"Satpati","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s10967-015-4290-3","article-title":"Preparation and evaluation of a single vial AMBA kit for 68Ga labelling with potential form imaging of GRP receptor-positive cancers","volume":"307","author":"Pandey","year":"2016","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpba.2018.09.045","article-title":"Single vial cold kits optimized for preparation of gastrin releasing peptide receptor (GRPR)-radioantagonsit 68Ga-RM2 using three different 68Ge\/68Ga-generators","volume":"163","author":"Vast","year":"2019","journal-title":"J Pharm Biomed Anal"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109678_bb0150","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3390\/pharmaceutics13081160","article-title":"68Ga-radiolabeling and pharmacological characterization of a kit-based formulation of the gastrin-releasing peptide receptor (GRP-R) antagonist RM2 for convenient preparation of [68Ga]Ga-RM2","volume":"13","author":"Chastel","year":"2021","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109678_bb0155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jlcr.3795","article-title":"Synthresis, radiolabelling, and evaluation of gastrin releasing peptide receptor antagonist 68Ga-HBED-CC-RM26","volume":"62","author":"Satpati","year":"2019","journal-title":"J Label Compd Radiopharm"},{"issue":"334","key":"10.1016\/j.nucmedbio.2026.109678_bb0160","first-page":"1183","article-title":"Radiochemical synthesis and pre-clinical evaluation of [68Ga]Ga-FAPI-4 formulated using in-house developed FAPI-4 kit","volume":"2024","author":"Sakhare","year":"2024","journal-title":"J Radioanal Nucl Chem"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109678_bb0165","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using 18F-ALF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0170","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejpb.2021.06.012","article-title":"Lyophilization of NOTA-sdAbs: first step towards a cold diagnostic kit for 68Ga-labeling","volume":"166","author":"Baudhuin","year":"2021","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2023.110725","article-title":"A robust lyophilized kit for convenient one-step formulation of [68Ga]Ga-DOTA-E-[c(RGDFK)]2 in hospital radiopharmacy for clinical pet imaging","volume":"196","author":"Das","year":"2023","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11307-016-1014-1","article-title":"Evaluation of a flexible NOTA-RGD kit solution using gallium-68 from different 68Ge\/68Ga generators: pharmacokinetics and biodistribution in nonhuman primates and demonstration of solitary pulmonary nodule imaging in humans","volume":"19","author":"Ebenhan","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0185","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1039\/C7MD00006E","article-title":"68Ga-chelation and comparative evaluation of N,N-bis-[2-hydroxy-5-(carboxyethyl)benzyl]-ethylenediamine-N,N\u2019-diacetic acid (HBED-CC) conjugated NGR and RGD peptides as tumor targeted molecular imaging probes","volume":"8","author":"Sapati","year":"2017","journal-title":"Med Chem Commun"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109678_bb0220","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1053\/j.ro.2025.04.005","article-title":"Lutetium-177 theranostics and dosimetry for neuroendocrine neoplasms and prostate cancer","volume":"60","author":"Wong","year":"2025","journal-title":"Semin Roentgenol"},{"issue":"8","key":"10.1016\/j.nucmedbio.2026.109678_bb0225","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1021\/cr500171e","article-title":"Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications","volume":"115","author":"Banerjee","year":"2015","journal-title":"Chem Rev"},{"issue":"3","key":"10.1016\/j.nucmedbio.2026.109678_bb0230","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1021\/acs.bioconjchem.0c00015","article-title":"Bioconjugates of chelators with peptides and proteins in nuclear medicine: historical importance, current innovations and future challenges","volume":"31","author":"Jackson","year":"2020","journal-title":"Bioconjug Chem"},{"issue":"9","key":"10.1016\/j.nucmedbio.2026.109678_bb0235","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/jlcr.3590","article-title":"Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers","volume":"61","author":"Boros","year":"2018","journal-title":"J Label Compd Radiopharm"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109678_bb0240","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3390\/pharmaceutics15071988","article-title":"Improving overall survival and quality of life in patients with prostate cancer and neuroendocrine tumors using 177Lu-iPSMA and 177Lu-DOTATOC: experience after 905 treatment doses","volume":"15","author":"Luna-Guti\u00e9rrez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0245","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s10967-017-5595-1","article-title":"Freeze-dried multi-dose kits for the fast preparation of 177Lu-Tyr3-octreotide and 177Lu-PSMA(inhibitor) under GMP conditions","volume":"314","author":"Luna-Guitierrez","year":"2017","journal-title":"J Radioanal Nucl Chem"},{"issue":"24","key":"10.1016\/j.nucmedbio.2026.109678_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262411783","article-title":"Enhancing cytosolic internalization of [177Lu]iPSMA in prostate cancer cells: the effect of conjugating a GRP78 inhibitor to the radiotherapeutic molecule","volume":"26","author":"Azorin-Vega","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0255","doi-asserted-by":"crossref","DOI":"10.1177\/1559325821990147","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy: indigenously developed freeze dried cold kit and biological response in in-vitro and in-vivo models","volume":"19","author":"Roohi","year":"2021","journal-title":"Dose Response"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109678_bb0260","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/jlcr.3267","article-title":"Single vial kit formulation of DOTATATE for preparation of (177)Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy","volume":"58","author":"Mukherjee","year":"2015","journal-title":"J Label Compd Radiopharm"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109678_bb0265","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/jlcr.4086","article-title":"Formulation of a patient dose of [177Lu]Trastuzumab using in-house developed freeze-dried kit: a path forward for clinical translation","volume":"67","author":"Amirdhanayagam","year":"2024","journal-title":"J Label Compd Radiopharm"},{"issue":"11","key":"10.1016\/j.nucmedbio.2026.109678_bb0270","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1515\/ract-2025-0043","article-title":"Development and evaluation of 177Lu-imatinib: radiolabeling and cell culture studies","volume":"113","author":"\u00d6zgen\u00e7","year":"2025","journal-title":"Radiochim Acta"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0275","first-page":"3709","article-title":"Environmental justice in South Africa: the dilemma of informal settlement residents","volume":"88","author":"Kekana","year":"2023","journal-title":"Geojournal"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109678_bb0280","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s00259-025-07678-1","article-title":"Theranostics and nuclear medicine practice in Asia-Pacific: an IAEA regional study","volume":"53","author":"Al-Ibraheem","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109678_bb0285","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2967\/jnumed.125.271248","article-title":"(2026). The current status of nuclear medicine in Africa","volume":"67","author":"Brink","year":"2026","journal-title":"J Nucl Med"},{"issue":"25","key":"10.1016\/j.nucmedbio.2026.109678_bb0290","first-page":"19","article-title":"Scalable 68Ga cold kit radiolabeling: high-throughput preparation of [68Ga]Ga-Edotreotide via aliquoting and dual generator strategy","volume":"2026","author":"Vanney","year":"2026","journal-title":"World J Nucl Med"},{"issue":"13","key":"10.1016\/j.nucmedbio.2026.109678_bb0295","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jlcr.3879","article-title":"Production of [68Ga]Ga-PSMA: comparing a manual kit-based method with a module-based automated synthesis approach","volume":"63","author":"Kleynhans","year":"2020","journal-title":"J Label Compd Radiopharm"},{"issue":"12","key":"10.1016\/j.nucmedbio.2026.109678_bb0300","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.3390\/molecules27123862","article-title":"Analysis of pros and cons in using [68Ga]Ga-PSMA11 and [18F]PSMA-1007: production, costs and PET\/CT applications in patients with prostate cancer","volume":"27","author":"Maisto","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vhri.2022.06.005","article-title":"Microcosting study of prostate- specific membrane antigen positron emission tomgoraphy\/computed tomography in prostate cancer","volume":"32","author":"Parkinson","year":"2022","journal-title":"Value Health Reg Issues"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0310","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/13696998.2023.2183618","article-title":"Costs of radium-223 and the pharmacy preperation of 177Lu-PSMA-I&T for metastatic castration resistant prostate cancer in Dutch hospitals","volume":"26","author":"Quist","year":"2023","journal-title":"J Med Econ"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0315","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s41181-020-00106-9","article-title":"Cyclotron-based production of 68Ga, [68Ga]GaCl3 and [68Ga]Ga-PSMA-11 from a liquid target","volume":"5","author":"Rodnick","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0320","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/pharmaceutics15010070","article-title":"Cyclotron production of gallium-68 radiopharmaceuticals using the 68Zn(p,n)68Ga reaction and their regulatory aspects","volume":"15","author":"Ashhar","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0325","series-title":"Handbook of radiopharmaceuticals","first-page":"291","article-title":"Labeling with Gallium-68","author":"Burke","year":"2021"},{"issue":"1091","key":"10.1016\/j.nucmedbio.2026.109678_bb0330","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180108","article-title":"Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy","volume":"91","author":"Pencharz","year":"2018","journal-title":"Br J Radiol"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0335","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of 177Lu for targeted radionuclide therapy: available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0340","series-title":"Poster presented at: SASMO SASCRO congress 7\u20139 august 2015","article-title":"Comparisons between high and low specific activity 177Lu and its significance to peptide receptor radiation therapy","author":"Knoesen","year":"2015"},{"issue":"2","key":"10.1016\/j.nucmedbio.2026.109678_bb0345","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/1874471008666150312162340","article-title":"Alternative method to determine specific activity of 177Lu by HPLC","volume":"8","author":"Breeman","year":"2015","journal-title":"Curr Radiopharm"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109678_bb0350","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1134\/S1066362219040015","article-title":"Production of lutetium-177: process aspects","volume":"61","author":"Kuznetsov","year":"2019","journal-title":"Radiochemistry"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0355","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1874471008666150313111131","article-title":"Overview of development and formulation of 177Lu-DOTA-Tate for PRRT","volume":"9","author":"Breeman","year":"2016","journal-title":"Curr Radiopharm"},{"issue":"4","key":"10.1016\/j.nucmedbio.2026.109678_bb0360","first-page":"265","article-title":"Practical aspects of peptide receptor radionuclide therapy with [177]Lu[DOTA0,Tyr3]octreotate","volume":"50","author":"Bakker","year":"2006","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"S3","key":"10.1016\/j.nucmedbio.2026.109678_bb0365","first-page":"1248","article-title":"177mLu impurity: practical aspects of 177mLu hospital waste management","volume":"56","author":"Maus","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2025.109582","article-title":"Recovery of zinc-89 from gallium-68 cyclotron target effluent: a method to establish wet chemistry capabilities for metal precursor recovery in PET radiometals","volume":"152-153","author":"Horn","year":"2026","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2020.109261","article-title":"Modelling of the 177mLu\/177Lu radionuclide generator","volume":"166","author":"Bhardwaj","year":"2020","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.enbuild.2019.109346","article-title":"Energy demand reduction in pharmaceutical cleanrooms through optimization of ventilation","volume":"202","author":"Loomans","year":"2019","journal-title":"Energ Buildings"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0385","series-title":"Cyclotron produced radionuclides: Physical characteristics and production methods","author":"International Atomic Energy Agency","year":"2009"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108892","article-title":"Improved purification of cyclotron [68Ga]GaCl3 for the production of 68Ga radiopharmaceuticals","volume":"130-131","author":"Wang","year":"2024","journal-title":"Nucl Med Biol"},{"issue":"17","key":"10.1016\/j.nucmedbio.2026.109678_bb0395","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.3390\/molecules30173458","article-title":"Evaluation of cyclotron solid target produced gallium-68 chloride for labelling of [68Ga]Ga-PSMA-11 and [68Ga]Ga-DOTATOC","volume":"30","author":"Jagodzinski","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0400","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13550-021-00765-y","article-title":"Evaluation of [68Ga]Ga-PSMA PET\/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision","volume":"11","author":"Weber","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0405","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40644-023-00540-3","article-title":"Long-axial field-of-view PET\/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients","volume":"23","author":"Alberts","year":"2023","journal-title":"Cancer Imaging"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109678_bb0410","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1055\/a-2198-0358","article-title":"Artificial intelligence and deep learning for advancing PET image reconstruction: state-of-the-art and future directions","volume":"62","author":"Hellwig","year":"2023","journal-title":"Nuklearmedizin"},{"issue":"1","key":"10.1016\/j.nucmedbio.2026.109678_bb0415","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1039\/C3CS60304K","article-title":"Matching chelators to radiometals for radiopharmaceuticals","volume":"43","author":"Price","year":"2014","journal-title":"Chem Soc Rev"},{"issue":"5","key":"10.1016\/j.nucmedbio.2026.109678_bb0420","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20230042","article-title":"Advances in macrocylic chelators for positron emission tomography imaging","volume":"4","author":"Li","year":"2023","journal-title":"View"},{"issue":"6","key":"10.1016\/j.nucmedbio.2026.109678_bb0425","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1039\/c0gc00797h","article-title":"Searching for green solvents","volume":"13","author":"Jessop","year":"2011","journal-title":"Green Chem"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0430","series-title":"Alternative solvents for green chemistry","author":"Ferton","year":"2013"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0435","author":"International Atomic Energy Agency"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0440","series-title":"Endotoxins: structure, function and recognition. Subcellular biochemistry","first-page":"187","article-title":"Endotoxin detection \u2013 from Limulus amebocyte lysate to recombinant factor C","volume":"vol. 53","author":"Ding","year":"2010"},{"key":"10.1016\/j.nucmedbio.2026.109678_bb0445","series-title":"Technetium-99m Radiopharmaceuticals: Manufacture of Kits, Technical Reports Series No. 466","author":"International Atomic Energy Agency","year":"2008"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:27:32Z","timestamp":1793028452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":83,"alternative-id":["S0969805126000776"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109678","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small-scale theranostic radiopharmaceutical production using cold kits: a green chemistry perspective","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109678"}}